The utility of recruitment incentives in early Alzheimer's disease trials.

ABSTRACT:

Introduction

Amid recent approvals, early Alzheimer's disease (AD) remains an active area of treatment development.

Methods

We performed a conjoint experiment to compare preferences among 26 patients with mild cognitive impairment for four trial features including designs incorporating active aducanumab-control (vs. placebo), returning tau positron emission tomography (PET) results (vs. no disclosure), remote study partner participation (vs. in person), and increased risk of brain swelling (vs. lower risk). We used a generalized estimating equation to model the utility of factor levels.

Results

Returning tau PET results had the highest utility (est: 0.47; 95% confidence interval [CI]: 0.13, 0.81; P = 0.007); remote study partner participation showed a similar trend (e

SUBMITTER: Ritchie M 

PROVIDER: S-EPMC11497734 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature